Glemont-F Tablet is a combination medication containing Montelukast 10 mg and Fexofenadine 120 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, works by blocking leukotriene D4 receptors in the airways, thereby reducing inflammation, bronchoconstriction, and mucus production. Fexofenadine, a second-generation antihistamine, selectively inhibits peripheral H1 receptors, alleviating symptoms like sneezing, nasal congestion, itching, and hives without causing significant sedation. The synergistic action of these two agents provides comprehensive relief from allergy symptoms by targeting multiple pathways involved in the allergic response. Glemont-F is typically administered orally once daily, with or without food, as prescribed by a healthcare professional. It is well-tolerated, with a low incidence of adverse effects; however, patients should be monitored for potential side effects such as headache, dizziness, gastrointestinal discomfort, or hypersensitivity reactions. This combination therapy is contraindicated in individuals with known hypersensitivity to either component. Glemont-F Tablet offers an effective and convenient option for patients requiring dual-action therapy for allergic disorders, improving quality of life by controlling symptoms and preventing exacerbations.